TaqMan amplification system with an internal positive control for HCV RNA quantitation

Area of Science:

• Virology
• Molecular Biology
• Clinical Diagnostics

Background:

• Quantifying hepatitis C virus (HCV) RNA is crucial for monitoring antiviral treatment efficacy in chronically infected patients.
• Existing quantitative HCV RNA assays primarily utilize branched DNA (bDNA) or reverse-transcription PCR (RT-PCR) amplification techniques.

Purpose of the Study:

• To develop and evaluate a novel RT-PCR assay employing TaqMan fluorescence-based real-time PCR with minor groove binding (MGB) probes for precise HCV RNA quantification.
• To establish a method for calculating HCV RNA concentration using an external standard curve and an internal positive control (IPC).

Main Methods:

• Design and implementation of a TaqMan RT-PCR assay for HCV RNA quantification.
• Utilizing an external standard curve and an internal positive control (IPC) for concentration determination.
• Validation of the assay's performance using clinical samples and comparison with established commercial assays (Amplicor HCV Monitor and bDNA VERSANT HCV RNA).

Main Results:

• The developed assay demonstrated high reproducibility with intra-assay (1.6% CV) and inter-assay (3.2% CV) coefficients of variation.
• It exhibited a linear quantification range from 550 to 10,000,000 IU/mL and accurately quantified major HCV genotypes.
• The assay showed significant correlation with commercial methods (R² = 0.9535 and R² = 0.8508).

Conclusions:

• The TaqMan HCV assay is highly reproducible and reliable for quantifying HCV RNA.
• This new technique provides an attractive and effective approach for measuring HCV viral load, yielding results comparable to commercial assays.
• The assay facilitates accurate monitoring of viral decline during antiviral therapy.